US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
US5541087A
(en)
*
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6086875A
(en)
*
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6030613A
(en)
*
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
JPH11505421A
(en)
*
|
1995-05-11 |
1999-05-21 |
ヒューマン ジノーム サイエンシーズ,インコーポレイテッド |
Human uridine diphosphate galactose-4-epimerase
|
EP0885012A4
(en)
*
|
1996-01-29 |
2001-09-05 |
Univ Georgetown |
Malaria vaccine based upon the addition of a msa1 peptide
|
US6962981B1
(en)
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
CA2250141C
(en)
*
|
1996-03-25 |
2008-07-29 |
Pacific Northwest Cancer Foundation |
Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
|
TW517061B
(en)
*
|
1996-03-29 |
2003-01-11 |
Pharmacia & Amp Upjohn Ab |
Modified/chimeric superantigens and their use
|
WO1997040033A1
(en)
*
|
1996-04-19 |
1997-10-30 |
Lexigen Pharmaceuticals Corp. |
Inhibition of the binding of human ige to its receptor by tetracyclic compounds for the alleviation of ige-mediated immune response
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
US20050003431A1
(en)
*
|
1996-08-16 |
2005-01-06 |
Wucherpfennig Kai W. |
Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
|
MX340738B
(en)
*
|
1996-09-13 |
2016-07-22 |
Shire Human Genetic Therapies |
THERAPY FOR α-GALACTOSIDASE A DEFICIENCY.
|
WO1998024886A1
(en)
*
|
1996-12-04 |
1998-06-11 |
Brigham And Women's Hospital, Inc. |
Mast cell protease that cleaves fibrinogen
|
ATE397061T1
(en)
*
|
1997-01-08 |
2008-06-15 |
Invitrogen Corp |
METHOD FOR PRODUCING PROTEINS
|
WO1998033812A1
(en)
*
|
1997-02-05 |
1998-08-06 |
Brigham And Women's Hospital, Inc. |
Mast cell protease peptide inhibitors
|
US6852508B1
(en)
*
|
1997-02-28 |
2005-02-08 |
Genetics Institute, Llc |
Chemokine with amino-terminal modifications
|
ATE361102T1
(en)
*
|
1997-07-21 |
2007-05-15 |
Active Biotech Ab |
CYTOLYSIS OF APPROPRIATE TARGET CELLS WITH SUPERANTIGEN CONJUGATES BY MEANS OF THE INDUCTION OF T-CELL ACTIVATION
|
US20030027257A1
(en)
*
|
1997-08-21 |
2003-02-06 |
University Technologies International, Inc. |
Sequences for improving the efficiency of secretion of non-secreted protein from mammalian and insect cells
|
US6037150A
(en)
*
|
1997-08-21 |
2000-03-14 |
University Technologies International Inc. |
Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells
|
US20020127584A1
(en)
*
|
1997-09-18 |
2002-09-12 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030022298A1
(en)
*
|
1997-09-15 |
2003-01-30 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030032103A1
(en)
*
|
1997-09-18 |
2003-02-13 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DK1037927T3
(en)
|
1997-12-08 |
2004-09-06 |
Emd Lexigen Res Ct Corp |
Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
EP1071468B1
(en)
*
|
1998-04-15 |
2006-06-14 |
Lexigen Pharmaceuticals Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
|
AU751823B2
(en)
*
|
1998-05-14 |
2002-08-29 |
Merck Patent Gmbh |
Fused protein
|
BR9913331A
(en)
*
|
1998-08-25 |
2001-05-15 |
Lexigen Pharm Corp |
Expression and export of angiogenesis inhibitors as immunofusins
|
TR200504220T2
(en)
*
|
1998-12-17 |
2007-04-24 |
Biogen Idec Ma Inc. |
Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
|
AU778939B2
(en)
*
|
1999-01-07 |
2004-12-23 |
Emd Lexigen Research Center Corp. |
Expression and export of anti-obesity proteins as Fc fusion proteins
|
AU3224700A
(en)
*
|
1999-02-08 |
2000-08-25 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
KR100312456B1
(en)
|
1999-03-13 |
2001-11-03 |
윤덕용 |
Gene Derived from Pseudomonas fluorescens Which Promotes the Secretion of Foreign Protein in Microorganism
|
EP1187852B1
(en)
*
|
1999-05-19 |
2007-08-08 |
EMD Lexigen Research Center Corp. |
EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
|
US6924359B1
(en)
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
WO2001008700A1
(en)
*
|
1999-07-28 |
2001-02-08 |
Genetics Institute, Inc. |
Preventing immune-mediated abortion by inhibiting costimulation
|
ATE316982T1
(en)
*
|
1999-08-09 |
2006-02-15 |
Lexigen Pharm Corp |
MULTIPLE CYTOKINE ANTIBODIES COMPLEXES
|
EP1731531B1
(en)
|
1999-08-09 |
2012-05-30 |
Merck Patent GmbH |
Multiple cytokine-antibody complexes
|
EP1228214A2
(en)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietin forms with improved properties
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
DE60122286T2
(en)
*
|
2000-02-11 |
2007-08-02 |
Merck Patent Gmbh |
INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
|
US20030064950A1
(en)
*
|
2001-02-23 |
2003-04-03 |
Ntambi James M. |
Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
|
EP1261721A1
(en)
*
|
2000-03-08 |
2002-12-04 |
MERCK PATENT GmbH |
Human extracellular signal regulated kinases
|
JP2003530120A
(en)
*
|
2000-04-05 |
2003-10-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
Novel lipid binding protein 1
|
US20030176338A1
(en)
*
|
2000-05-05 |
2003-09-18 |
Klaus Ducker |
Novel serine-threonine kinase
|
AU2001262996A1
(en)
*
|
2000-05-08 |
2001-11-20 |
Georgetown University |
Malaria vaccine and methods thereof based upon novel antigenic domain of plasmodium falciparum
|
JP2003532418A
(en)
*
|
2000-05-12 |
2003-11-05 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
New regulator of G-protein signal
|
BR0112111A
(en)
*
|
2000-06-29 |
2003-05-06 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers
|
UA83458C2
(en)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
|
EP1421190A2
(en)
*
|
2001-01-16 |
2004-05-26 |
Genset |
Metabolic gene polynucleotides and polypeptides and uses thereof
|
CA2440221C
(en)
*
|
2001-03-07 |
2013-02-05 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
EP1395279B1
(en)
|
2001-03-28 |
2011-10-05 |
Biogen Idec MA Inc. |
Use of neublastin polypeptides for treating neuropathic pain
|
US6992174B2
(en)
*
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
DE60239454D1
(en)
*
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE
|
GB0112818D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Lorantis Ltd |
Conjugate
|
US20050106659A1
(en)
*
|
2001-08-27 |
2005-05-19 |
Klemens Kaupmann |
Novel g-protein coupled receptor and dna sequences thereof
|
AU2002339862A1
(en)
*
|
2001-09-04 |
2003-05-26 |
Aventis Pharmaceuticals Inc. |
Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
|
US20030049694A1
(en)
*
|
2001-09-10 |
2003-03-13 |
Chung-Hsiun Wu |
Production of fusion proteins and use for identifying binding molecules
|
US6800462B2
(en)
*
|
2001-09-10 |
2004-10-05 |
Abgenomics Corporation |
Production of recombinant proteins in vivo and use for generating antibodies
|
EP1448588A4
(en)
|
2001-10-23 |
2006-10-25 |
Psma Dev Company L L C |
Psma antibodies and protein multimers
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
WO2003048334A2
(en)
*
|
2001-12-04 |
2003-06-12 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
AU2002358110A1
(en)
*
|
2001-12-10 |
2003-07-09 |
Novartis Ag |
Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
US20040063912A1
(en)
*
|
2002-03-15 |
2004-04-01 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
US20050208044A1
(en)
*
|
2002-03-19 |
2005-09-22 |
Jane Barclay |
Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
|
AU2003234717A1
(en)
*
|
2002-04-12 |
2003-10-27 |
Bristol-Myers Squibb Company |
Novel polynucleotides encoding the human citron kinase polypeptide, bmsnkc 0020/0021
|
PT1512014E
(en)
|
2002-06-13 |
2009-11-10 |
Merck Patent Gmbh |
Methods for the identification of all-antigens and their use for cancer therapy and transplantation
|
US8025873B2
(en)
|
2002-06-20 |
2011-09-27 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
US8029803B2
(en)
*
|
2002-06-20 |
2011-10-04 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
US20040052777A1
(en)
*
|
2002-09-04 |
2004-03-18 |
Mark Nesbit |
Kringle polypeptides and methods for using them to inhibit angiogenesis
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
CA2510180C
(en)
*
|
2002-12-17 |
2012-09-11 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
PT1585546E
(en)
|
2002-12-30 |
2008-11-14 |
Biogen Idec Inc |
Kim-1 antagonists and use to modulate immune system
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
AU2004257142A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
US8007805B2
(en)
|
2003-08-08 |
2011-08-30 |
Paladin Labs, Inc. |
Chimeric antigens for breaking host tolerance to foreign antigens
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
WO2005077981A2
(en)
*
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
WO2005063820A2
(en)
*
|
2003-12-30 |
2005-07-14 |
Merck Patent Gmbh |
Il-7 fusion proteins
|
EP1699821B1
(en)
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
|
AU2005206277B2
(en)
|
2004-01-22 |
2011-06-23 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
AU2005227326B2
(en)
*
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
AU2005286662B2
(en)
|
2004-09-23 |
2011-10-06 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
DK2325207T3
(en)
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
KR20070085886A
(en)
*
|
2004-12-09 |
2007-08-27 |
메르크 파텐트 게엠베하 |
Il-7 variants with reduced immunogenicity
|
TW200633718A
(en)
*
|
2004-12-16 |
2006-10-01 |
Applied Research Systems |
Treatment of hepatitis c in the asian population
|
CN100515491C
(en)
*
|
2005-01-04 |
2009-07-22 |
健能隆医药技术(上海)有限公司 |
Medical use of interleukin-22
|
EP1858925A2
(en)
*
|
2005-01-12 |
2007-11-28 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
CA2598454C
(en)
|
2005-02-18 |
2013-04-09 |
Medarex, Inc. |
Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
|
US7566456B2
(en)
*
|
2005-06-23 |
2009-07-28 |
Haiming Chen |
Allergen vaccine proteins for the treatment and prevention of allergic diseases
|
WO2007025991A2
(en)
*
|
2005-09-01 |
2007-03-08 |
Ares Trading S.A. |
Treatment of optic neuritis
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
EP1934341A1
(en)
*
|
2005-10-03 |
2008-06-25 |
AstraZeneca AB |
Fusion proteins having a modulated half-life in plasma
|
CA2624189A1
(en)
*
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
JP4860703B2
(en)
*
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
Optimized anti-CD30 antibody
|
JP2009521503A
(en)
*
|
2005-12-22 |
2009-06-04 |
ディー・エイチ・ワイ・アンド・カンパニー・リミテッド |
Antibodies against interleukin-22 binding proteins and their use for the treatment of metabolic diseases
|
JP5175214B2
(en)
*
|
2005-12-30 |
2013-04-03 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Interleukin-12P40 variant with improved stability
|
BRPI0620795A2
(en)
|
2005-12-30 |
2011-11-22 |
Merck Patent Ges Mit Beschronkter Haftung |
anti-cd19 antibodies reduced immunogenicity
|
US20070179094A1
(en)
|
2006-01-31 |
2007-08-02 |
Bayer Schering Pharma Ag |
Modulation of MDL-1 activity for treatment of inflammatory disease
|
US8940871B2
(en)
|
2006-03-20 |
2015-01-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
|
WO2007109733A2
(en)
|
2006-03-21 |
2007-09-27 |
The Johns Hopkins University |
Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
|
JP2009537605A
(en)
|
2006-05-24 |
2009-10-29 |
メルク セローノ ソシエテ アノニム |
Cladribine regimen for the treatment of multiple sclerosis
|
AU2007271398B2
(en)
*
|
2006-07-06 |
2013-06-20 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
|
EP2069386A4
(en)
|
2006-07-21 |
2009-10-28 |
Life Technologies Corp |
Sharply resolving labeled protein molecular weight standards
|
ES2457072T3
(en)
|
2006-08-14 |
2014-04-24 |
Xencor, Inc. |
Optimized antibodies that select as target CD19
|
CA2660795C
(en)
*
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
EP2073833A2
(en)
*
|
2006-10-20 |
2009-07-01 |
Biogen Idec MA Inc. |
Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
|
US8338376B2
(en)
*
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
CN111518218A
(en)
|
2006-11-02 |
2020-08-11 |
阿塞勒隆制药公司 |
ALK1 receptor and ligand antagonists and uses thereof
|
PE20081250A1
(en)
*
|
2006-11-28 |
2008-10-07 |
Centelion |
Fc FUSIONS WITH RECEIVER FOR MODIFIED SOLUBLE FGF, WITH IMPROVED BIOLOGICAL ACTIVITY
|
TW200907056A
(en)
*
|
2007-03-28 |
2009-02-16 |
Astrazeneca Ab |
New method
|
DK2160401T3
(en)
|
2007-05-11 |
2014-10-20 |
Altor Bioscience Corp |
Fusion Molecules and IL-15 Variants
|
CN103641919B
(en)
|
2007-05-30 |
2017-04-05 |
浦项工科大学校产学协力团 |
Domain-immunoglobulin fusion proteins
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
EP4098661A1
(en)
|
2007-12-26 |
2022-12-07 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
CN105963695A
(en)
|
2008-05-02 |
2016-09-28 |
阿塞勒隆制药公司 |
Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage
|
PT2352763E
(en)
*
|
2008-10-01 |
2016-06-02 |
Amgen Res (Munich) Gmbh |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
KR101026526B1
(en)
*
|
2009-01-23 |
2011-04-01 |
한국과학기술연구원 |
Method for the secretory production of heterologous protein in Escherichia coli
|
EP3495000A1
(en)
|
2009-02-17 |
2019-06-12 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
CN102405230A
(en)
*
|
2009-04-22 |
2012-04-04 |
默克专利有限公司 |
Antibody fusion proteins with modified fcrn binding sites
|
JP6166041B2
(en)
|
2009-06-15 |
2017-07-19 |
バレリオン セラピューティクス, エルエルシー |
Methods and compositions for treating tubule myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptide
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
KR101061017B1
(en)
*
|
2009-10-23 |
2011-08-31 |
(주) 수파드엘릭사 |
Pharmaceutical composition for inhibiting growth and / or metastasis of cancer cells
|
CA2782333C
(en)
|
2009-12-02 |
2019-06-04 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
US8637637B2
(en)
|
2010-01-12 |
2014-01-28 |
Bill Nai-Chau Sun |
Fc fusion proteins of human growth hormone
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
CN102947341B
(en)
|
2010-01-19 |
2018-07-06 |
哈佛大学校长及研究员协会 |
For pathogen detection and the engineering opsonin for the treatment of
|
AU2011218294A1
(en)
|
2010-02-16 |
2012-08-30 |
Medimmune, Llc |
HSA-related compositions and methods of use
|
EP2563385B1
(en)
*
|
2010-04-28 |
2017-08-02 |
Oncoimmune Inc. |
Methods of use of soluble cd24 for therapy of rheumatoid arthritis
|
US20130231464A1
(en)
|
2010-04-28 |
2013-09-05 |
Oncolmmune, Inc. |
Methods of use of soluble cd24 for therapy of rheumatoid arthritis
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
EP2918607B1
(en)
|
2010-09-21 |
2017-11-08 |
Altor BioScience Corporation |
Multimeric il-15 soluble fusion molecules and methods of making and using same
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
EP2680874A2
(en)
|
2011-03-04 |
2014-01-08 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
CN108341863A
(en)
|
2011-04-20 |
2018-07-31 |
阿塞勒隆制药公司 |
Endoglin polypeptide and application thereof
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
AU2014207549B2
(en)
|
2013-01-15 |
2018-12-06 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN105189542A
(en)
|
2013-02-20 |
2015-12-23 |
瓦莱里昂治疗有限责任公司 |
Methods and compositions for treatment of pompe disease
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
LT2981822T
(en)
|
2013-05-06 |
2020-12-28 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
US20150056199A1
(en)
|
2013-08-22 |
2015-02-26 |
Acceleron Pharma, Inc. |
Tgf-beta receptor type ii variants and uses thereof
|
KR102354787B1
(en)
|
2013-10-25 |
2022-01-24 |
악셀레론 파마 인코포레이티드 |
Endoglin peptides to treat fibrotic diseases
|
WO2015085311A1
(en)
|
2013-12-07 |
2015-06-11 |
Case Western Reserve University |
Compositions and methods of treating thrombosis
|
EP3094646B1
(en)
|
2014-01-13 |
2020-04-15 |
Valerion Therapeutics, LLC |
Internalizing moieties
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015237184B2
(en)
|
2014-03-28 |
2020-11-26 |
Xencor, Inc. |
Bispecific antibodies that bind to CD38 and CD3
|
AU2015269333B2
(en)
|
2014-06-04 |
2020-05-07 |
Acceleron Pharma, Inc. |
Methods and compositions for treatment of disorders with follistatin polypeptides
|
ES2899890T3
(en)
|
2014-06-30 |
2022-03-15 |
Altor Bioscience Corp |
IL-15-based molecules and methods of using the same
|
EP3677285B1
(en)
|
2014-08-04 |
2023-12-13 |
Case Western Reserve University |
Targeting peptides for detecting prostate cancer
|
US10603359B2
(en)
|
2014-10-30 |
2020-03-31 |
Acceleron Pharma Inc. |
Methods and compositions using GDF15 polypeptides for increasing red blood cells
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
TN2017000222A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
CU24597B1
(en)
|
2014-11-26 |
2022-05-11 |
Xencor Inc |
HETERODIMERIC BIESPECIFIC ANTIBODIES THAT BIND CD3 AND CD20
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
ES2901273T3
(en)
|
2015-04-06 |
2022-03-21 |
Subdomain Llc |
De novo binding domain-containing polypeptides and uses thereof
|
CN107849117B
(en)
|
2015-06-05 |
2022-08-26 |
艾比欧公司 |
Endostatin fragments and variants for the treatment of fibrosis
|
EP4218792A1
(en)
|
2015-08-04 |
2023-08-02 |
Acceleron Pharma Inc. |
Composition for treating myeloproliferative disorders
|
EP4137158A1
(en)
|
2015-08-07 |
2023-02-22 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
KR102463844B1
(en)
|
2016-05-27 |
2022-11-08 |
알토 바이오사이언스 코포레이션 |
Construction and Characterization of Multimeric IL-15-Based Molecules with CD3 Binding Domains
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
KR20190020341A
(en)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
Heterozygous antibodies that bind to somatostatin receptor 2
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
JP7142630B2
(en)
|
2016-10-14 |
2022-09-27 |
ゼンコア インコーポレイテッド |
IL15/IL15Rα heterodimeric FC-fusion protein
|
KR102392142B1
(en)
|
2016-10-21 |
2022-04-28 |
알토 바이오사이언스 코포레이션 |
Mutimeric IL-15-Based Molecules
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
CA3216726A1
(en)
|
2017-03-06 |
2018-09-13 |
Altor Bioscience Corporation |
Il-15-based fusions to il-12 and il-18
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
WO2018204594A1
(en)
|
2017-05-04 |
2018-11-08 |
Acceleron Pharma Inc. |
Tgf-beta receptor type ii fusion proteins and uses thereof
|
EP3630158B1
(en)
*
|
2017-05-22 |
2022-07-13 |
Oncoimmune, Inc. |
Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
WO2019046313A1
(en)
|
2017-08-28 |
2019-03-07 |
Altor Bioscience Llc |
Il-15-based fusions to il-7 and il-21
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2018369639A1
(en)
|
2017-11-14 |
2020-04-23 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
MX2020004935A
(en)
|
2017-11-14 |
2020-09-25 |
Arcellx Inc |
Multifunctional immune cell therapies.
|
KR20230019227A
(en)
*
|
2017-11-17 |
2023-02-07 |
그리폴스 다이어그노스틱 솔루션즈 인크. |
Novel mammalian expressed human immunodeficiency virus envelope protein antigens
|
WO2019125732A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
US11168138B2
(en)
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
JP2021521784A
(en)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
CN110964116A
(en)
|
2018-09-26 |
2020-04-07 |
北京辅仁瑞辉生物医药研究院有限公司 |
GLP1-Fc fusion proteins and conjugates thereof
|
CN113195523A
(en)
|
2018-10-03 |
2021-07-30 |
Xencor股份有限公司 |
IL-12 heterodimer Fc fusion proteins
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
WO2022065643A1
(en)
*
|
2020-09-28 |
2022-03-31 |
한국화학연구원 |
Recombinant microorganism comprising polynucleotide encoding target product binding protein fused to secretion signal sequence, composition comprising same, and method for producing target product by using same
|
KR102625766B1
(en)
*
|
2020-09-28 |
2024-01-17 |
한국화학연구원 |
Recombinant microorganism comprising polynucleotide encoding target product binding protein fused to export signal sequence, composition comprising the same and method of producing target product using the same
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
KR20230154311A
(en)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Heterodimeric antibodies binding to CD3 and GPC3
|